RU2010129685A - Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом - Google Patents
Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом Download PDFInfo
- Publication number
- RU2010129685A RU2010129685A RU2010129685/15A RU2010129685A RU2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685/15 A RU2010129685/15 A RU 2010129685/15A RU 2010129685 A RU2010129685 A RU 2010129685A RU 2010129685 A RU2010129685 A RU 2010129685A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- probiotic
- composition
- bifidobacterium
- opportunistic infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы. ! 2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза. ! 3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999. ! 4. Композиция по п.1, которая является детской смесью. ! 5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции. ! 6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси. ! 7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси. ! 8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции. ! 9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика. ! 10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом. ! 11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa. ! 12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, явл�
Claims (12)
1. Композиция, подходящая для применения в предупреждении оппортунистических инфекций у индивидуумов с нарушенным иммунитетом, содержащая пробиотик Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve или Bifidobacterium longum и фукозилированный олигосахарид, выбираемый из группы, состоящей из 2'-фукозиллактозы, 3'-фукозиллактозы, дифукозиллактозы, лакто-N-фукопентаозы, лакто-N-фукогексаозы, фукозиллакто-N-гексаозы и фукозиллакто-N-неогексаозы.
2. Композиция по п.1, в которой фукозилированным олигосахаридом является 2'-фукозиллактоза.
3. Композиция по п.1 или 2, в которой пробиотиком является Bifidobacterium lactis CNCM 1-3446 или Bifidobacterium longum АТСС BAA-999.
4. Композиция по п.1, которая является детской смесью.
5. Композиция по п.4, которая содержит от 0,1 до 3 г фукозилированного олигосахарида на 100 г композиции.
6. Композиция по п.4 или 5, которая содержит от 103 до 1012 КОЕ пробиотика на 1 г детской смеси.
7. Композиция по п.5, которая содержит от 106 до 109 КОЕ пробиотика на 1 г детской смеси.
8. Композиция по п.5, которая дополнительно содержит по меньшей мере один пребиотик в количестве от 0,3 до 19 мас.% от композиции.
9. Композиция по п.1, которая является биологически активной добавкой и которая содержит в разовой дозе от 0,1 до 3 г фукозилированного олигосахарида и от 105 до 1012 КОЕ пробиотика.
10. Применение композиции по любому из пп.1-9 в производстве лекарственных средств или терапевтической питательной композиции для предупреждения оппортунистических инфекций у индивидуумов с нарушенным иммунитетом.
11. Применение по п.10, в котором возбудителем оппортунистической инфекции является Pseudomonas aeroginosa.
12. Применение по п.10, в котором инфекция, возбуждаемая Pseudomonas aeroginosa, является инфекцией дыхательных, мочевых или желудочно-кишечного путей.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07123390A EP2072052A1 (en) | 2007-12-17 | 2007-12-17 | Prevention of opportunistic infections in immune-compromised subjects |
| EP07123390.2 | 2007-12-17 | ||
| PCT/EP2008/066850 WO2009077352A1 (en) | 2007-12-17 | 2008-12-05 | Prevention of opportunistic infections in immune-compromised subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010129685A true RU2010129685A (ru) | 2012-01-27 |
| RU2486910C2 RU2486910C2 (ru) | 2013-07-10 |
Family
ID=39111664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010129685/15A RU2486910C2 (ru) | 2007-12-17 | 2008-12-05 | Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9217133B2 (ru) |
| EP (2) | EP2072052A1 (ru) |
| CN (1) | CN101909644A (ru) |
| AU (1) | AU2008337646B2 (ru) |
| BR (1) | BRPI0820837A2 (ru) |
| CA (1) | CA2709396A1 (ru) |
| ES (1) | ES2576642T3 (ru) |
| IN (1) | IN2010DE04311A (ru) |
| MX (1) | MX2010006690A (ru) |
| MY (1) | MY185938A (ru) |
| PH (1) | PH12010501367B1 (ru) |
| PL (1) | PL2234627T3 (ru) |
| PT (1) | PT2234627T (ru) |
| RU (1) | RU2486910C2 (ru) |
| SG (1) | SG186657A1 (ru) |
| UA (1) | UA102830C2 (ru) |
| WO (1) | WO2009077352A1 (ru) |
| ZA (1) | ZA201005088B (ru) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009033011A1 (en) | 2007-09-07 | 2009-03-12 | Children's Hospital Medical Center | Use of secretor, lewis and sialyl antigen levels as predictors for disease |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| JP2012532195A (ja) | 2009-07-06 | 2012-12-13 | チルドレンズ ホスピタル メディカル センター | 乳オリゴ糖による炎症の阻害 |
| EP2813230A1 (en) | 2009-07-15 | 2014-12-17 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing infections |
| CN107087793A (zh) * | 2009-07-15 | 2017-08-25 | N·V·努特里奇亚 | 用于刺激免疫系统的不可消化低聚糖的混合物 |
| US9408880B2 (en) | 2013-12-20 | 2016-08-09 | Katherine Rose Kovarik | Method and system for prevention and treatment of allergic and inflammatory diseases |
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US9457077B2 (en) | 2009-11-18 | 2016-10-04 | Katherine Rose Kovarik | Method and system for targeting the microbiome to promote health and treat allergic and inflammatory diseases |
| CN102946742A (zh) * | 2010-04-27 | 2013-02-27 | N·V·努特里奇亚 | 人乳寡糖在婴儿营养物中的用途 |
| WO2011136637A1 (en) * | 2010-04-27 | 2011-11-03 | N.V. Nutricia | Use of human milk oligosaccharides in infant nutrition |
| WO2011150939A1 (en) | 2010-06-01 | 2011-12-08 | Glycom A/S | Polymorphs of 2'-o-fucosyllactose and producing thereof |
| EP2455387A1 (en) | 2010-11-23 | 2012-05-23 | Nestec S.A. | Oligosaccharide mixture and food product comprising this mixture, especially infant formula |
| EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
| EP2465509A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Oligosaccharide composition for treating acute respiratory tract infections |
| EP2658546B1 (en) | 2010-12-31 | 2018-12-05 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
| WO2012092156A1 (en) | 2010-12-31 | 2012-07-05 | Abbott Laboratories | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
| SG191799A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated polyunsaturated fatty acids and uses thereof |
| BR112013016606A2 (pt) * | 2010-12-31 | 2016-09-27 | Abbott Lab | processos para redução de incidência de tensão oxidante usando oligossacarídeos de leite humano, vitamina c e agentes antiflamatórios |
| BR112013015951A2 (pt) | 2010-12-31 | 2018-07-10 | Abbott Lab | composições nutricionais compreendendo oligossacarídeos e nucleotídeos de leite humano e usos destas para tratar e/ou prevenir infecção viral entérica. |
| NZ612105A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides for modulating inflammation |
| CN103763940B (zh) * | 2010-12-31 | 2015-10-14 | 雅培制药有限公司 | 促进有益微生物群生长的益生菌和人乳寡糖的合益素组合 |
| SG10201707519PA (en) * | 2010-12-31 | 2017-10-30 | Abbott Lab | Neutral human milk oligosaccharides to promote growth of beneficial bacteria |
| US10314865B2 (en) | 2011-02-04 | 2019-06-11 | Katherine Rose Kovarik | Method and system for treating cancer and other age-related diseases by extending the healthspan of a human |
| US10512661B2 (en) | 2011-02-04 | 2019-12-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US9730967B2 (en) | 2011-02-04 | 2017-08-15 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US11523934B2 (en) | 2011-02-04 | 2022-12-13 | Seed Health, Inc. | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US10245288B2 (en) | 2011-02-04 | 2019-04-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease |
| US10548761B2 (en) | 2011-02-04 | 2020-02-04 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US10111913B2 (en) | 2011-02-04 | 2018-10-30 | Joseph E. Kovarik | Method of reducing the likelihood of skin cancer in an individual human being |
| US10085938B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for preventing sore throat in humans |
| US11273187B2 (en) | 2015-11-30 | 2022-03-15 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing depression in an individual |
| US11844720B2 (en) | 2011-02-04 | 2023-12-19 | Seed Health, Inc. | Method and system to reduce the likelihood of dental caries and halitosis |
| US10086018B2 (en) | 2011-02-04 | 2018-10-02 | Joseph E. Kovarik | Method and system for reducing the likelihood of colorectal cancer in a human being |
| US11357722B2 (en) | 2011-02-04 | 2022-06-14 | Seed Health, Inc. | Method and system for preventing sore throat in humans |
| US9987224B2 (en) | 2011-02-04 | 2018-06-05 | Joseph E. Kovarik | Method and system for preventing migraine headaches, cluster headaches and dizziness |
| US10583033B2 (en) | 2011-02-04 | 2020-03-10 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US11191665B2 (en) | 2011-02-04 | 2021-12-07 | Joseph E. Kovarik | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| US10010568B2 (en) | 2011-02-04 | 2018-07-03 | Katherine Rose Kovarik | Method and system for reducing the likelihood of a spirochetes infection in a human being |
| US10687975B2 (en) | 2011-02-04 | 2020-06-23 | Joseph E. Kovarik | Method and system to facilitate the growth of desired bacteria in a human's mouth |
| US11998479B2 (en) | 2011-02-04 | 2024-06-04 | Seed Health, Inc. | Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure |
| US11951139B2 (en) | 2015-11-30 | 2024-04-09 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10842834B2 (en) | 2016-01-06 | 2020-11-24 | Joseph E. Kovarik | Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease |
| US11419903B2 (en) | 2015-11-30 | 2022-08-23 | Seed Health, Inc. | Method and system for reducing the likelihood of osteoporosis |
| US10835560B2 (en) | 2013-12-20 | 2020-11-17 | Joseph E. Kovarik | Reducing the likelihood of skin cancer in an individual human being |
| US11951140B2 (en) | 2011-02-04 | 2024-04-09 | Seed Health, Inc. | Modulation of an individual's gut microbiome to address osteoporosis and bone disease |
| BR112013020108A2 (pt) † | 2011-02-10 | 2017-06-13 | Nestec Sa | modulação do crescimento de bifidobactérias usando uma combinação de oligossacarídeos encontrados no leite de ser humano |
| US9567361B2 (en) * | 2011-05-13 | 2017-02-14 | Glycosyn LLC | Use of purified 2′-fucosyllactose, 3-fucosyllactose and lactodifucotetraose as prebiotics |
| CN103997899B (zh) | 2011-06-20 | 2016-04-20 | H.J.亨氏公司 | 益生菌组合物和方法 |
| ES2657744T3 (es) * | 2011-07-22 | 2018-03-06 | Abbott Laboratories | Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal |
| US10639319B2 (en) | 2011-08-29 | 2020-05-05 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
| RU2604503C2 (ru) * | 2011-10-18 | 2016-12-10 | Нестек С.А. | Композиция для применения при повышении чувствительности к инсулину и/или снижении инсулинорезистентности |
| US20140286908A1 (en) * | 2011-10-18 | 2014-09-25 | Nestec S.A. | Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery |
| CN108771687A (zh) | 2012-02-29 | 2018-11-09 | 伊西康内外科公司 | 微生物区系的组合物及与其相关的方法 |
| US20150064220A1 (en) * | 2012-03-27 | 2015-03-05 | Abbott Laboratories | Methods for modulating cell-mediated immunity using human milk oligosaccharides |
| ES2572831T3 (es) * | 2012-09-14 | 2016-06-02 | Abbott Laboratories | Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico |
| WO2014130789A1 (en) | 2013-02-21 | 2014-08-28 | Children's Hospital Medical Center | Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease |
| US10165788B2 (en) * | 2013-06-17 | 2019-01-01 | The Regents Of The University Of California | Methods and compositions for improved digestion of milk oligosaccharides |
| EP2815757A1 (en) * | 2013-06-17 | 2014-12-24 | Hestia Investments | Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa |
| AU2014350156A1 (en) | 2013-11-15 | 2016-04-14 | Nestec S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section |
| EP3071208B1 (en) | 2013-11-15 | 2021-08-11 | Société des Produits Nestlé S.A. | Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children |
| PT3111942T (pt) | 2013-11-15 | 2021-03-23 | Nestle Sa | Composições para utilização na prevenção ou tratamento de infecções do urt em lactentes ou crianças pequenas em risco |
| WO2015077233A1 (en) | 2013-11-19 | 2015-05-28 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
| US11969445B2 (en) | 2013-12-20 | 2024-04-30 | Seed Health, Inc. | Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH |
| US11833177B2 (en) | 2013-12-20 | 2023-12-05 | Seed Health, Inc. | Probiotic to enhance an individual's skin microbiome |
| US11980643B2 (en) | 2013-12-20 | 2024-05-14 | Seed Health, Inc. | Method and system to modify an individual's gut-brain axis to provide neurocognitive protection |
| US11826388B2 (en) | 2013-12-20 | 2023-11-28 | Seed Health, Inc. | Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation |
| US11998574B2 (en) | 2013-12-20 | 2024-06-04 | Seed Health, Inc. | Method and system for modulating an individual's skin microbiome |
| US12005085B2 (en) | 2013-12-20 | 2024-06-11 | Seed Health, Inc. | Probiotic method and composition for maintaining a healthy vaginal microbiome |
| US11839632B2 (en) | 2013-12-20 | 2023-12-12 | Seed Health, Inc. | Topical application of CRISPR-modified bacteria to treat acne vulgaris |
| EP3673909A1 (en) | 2014-04-08 | 2020-07-01 | Abbott Laboratories | Nutritional compositions for use in treating enteric infection comprising human milk oligosaccharides |
| CA2965663C (en) * | 2014-10-24 | 2023-04-04 | Evolve Biosystems, Inc. | Activated bifidobacteria and methods of use thereof |
| EP3881680A1 (en) | 2014-10-31 | 2021-09-22 | Pendulum Therapeutics, Inc. | Methods and compositions relating to microbial treatment |
| US20170354696A1 (en) * | 2014-11-26 | 2017-12-14 | Abbott Laboratories | Infant formula with rrr-alpha-tocopherol, 2'-fucosyllactose, and a probiotic |
| US10881674B2 (en) | 2014-12-08 | 2021-01-05 | Glycom A/S | Synthetic composition for treating metabolic disorders |
| US10987368B2 (en) | 2014-12-08 | 2021-04-27 | Glycom A/S | Synthetic composition for preventing or treating CVD |
| US10835544B2 (en) | 2014-12-08 | 2020-11-17 | Glycom A/S | Synthetic composition for regulating satiety |
| EP3265099B1 (en) * | 2015-03-05 | 2023-08-09 | Glycom A/S | Human milk oligosaccharides for treating acute respiratory tract infections |
| WO2016139330A1 (en) * | 2015-03-05 | 2016-09-09 | Nestec S.A. | Compositions for use in improving stool consistency or frequency in infants or young children |
| RU2720201C2 (ru) | 2015-03-05 | 2020-04-27 | Сосьете Де Продюи Нестле С.А. | Композиции для применения в профилактике или лечении отита или бронхита у младенцев или детей младшего возраста |
| US10709721B2 (en) | 2015-03-05 | 2020-07-14 | Societe Des Produits Nestle S.A. | Compositions for use in the prevention or treatment of gastrointestinal infections/inflammations in infants or young children |
| US10857167B2 (en) | 2015-04-28 | 2020-12-08 | Children's Hospital Medical Center | Use of oligosaccharide compositions to enhance weight gain |
| CA3017357A1 (en) * | 2016-03-11 | 2017-09-14 | Evolve Biosystems, Inc. | A transient commensal microorganism for improving gut health |
| EP3471562A4 (en) * | 2016-06-15 | 2020-07-29 | Glycom A/S | SYNTHETIC COMPOSITIONS WITH MOTHER MILK OLIGOSACCHARIDES FOR THE PREVENTION AND TREATMENT OF DISEASES |
| WO2019031961A1 (en) | 2017-08-11 | 2019-02-14 | N.V. Nutricia | OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION |
| CA3073838A1 (en) | 2017-08-30 | 2019-03-07 | Pendulum Therapeutics, Inc. | Methods and compositions for treatment of microbiome-associated disorders |
| EP3583858A1 (en) * | 2018-06-20 | 2019-12-25 | DuPont Nutrition Biosciences ApS | Compositions for treating or preventing gut barrier dysfunction |
| US11554131B2 (en) * | 2018-05-31 | 2023-01-17 | Glycom A/S | Mixture of HMOs for treating autoimmune diseases |
| EP3981256A4 (en) * | 2019-06-05 | 2023-01-25 | Morinaga Milk Industry Co., Ltd. | COMPOSITION |
| CA3158836A1 (en) * | 2019-11-20 | 2021-05-27 | Abbott Laboratories | Nutritional compositions for treating a clostridium difficile infection |
| CN112870233B (zh) * | 2019-11-29 | 2024-08-23 | 伊利伊诺科技(上海)有限责任公司 | 包含乳双歧杆菌与母乳低聚糖的组合物及其应用 |
| CN113491289A (zh) * | 2020-04-03 | 2021-10-12 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染的抵御能力的母乳低聚糖 |
| AU2021377524A1 (en) * | 2020-11-16 | 2023-07-06 | Inner Mongolia Dairy Tech Res Institute Co Ltd | Composition containing bifidobacterium lactis and human milk oligosaccharides and application thereof |
| CN116195629A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 婴儿双歧杆菌ylgb-1496在抗衰老、提高先天免疫方面的新应用 |
| CN116195740A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物 |
| WO2024013393A1 (en) * | 2022-07-15 | 2024-01-18 | Dsm Ip Assets B.V. | Combination of bifidobacterium and fucosylated hmo for use in increasing nmn or nad+ |
| TW202428293A (zh) * | 2022-09-27 | 2024-07-16 | 瑞士商雀巢製品股份有限公司 | 長雙歧桿菌過渡微生物之用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| DE69219768T2 (de) * | 1992-07-06 | 1997-08-28 | Societe Des Produits Nestle S.A., Vevey | Milchbakterien |
| ES2111625T3 (es) | 1992-07-06 | 1998-03-16 | Nestle Sa | Agente antigastritis. |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| WO1999017788A1 (en) * | 1997-10-06 | 1999-04-15 | Abbott Laboratories | Composition of treatment of candidiasis |
| US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
| US20020019991A1 (en) * | 1998-04-30 | 2002-02-14 | Abbott Laboratories | Compositions containing an alpha 1,2-fucose linkage and uses thereof |
| US6841149B1 (en) * | 1998-05-29 | 2005-01-11 | Agri-King, Inc. | Probiotic mixture intended for monogastric animals to control intestinal flora populations |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| US7101565B2 (en) * | 2002-02-05 | 2006-09-05 | Corpak Medsystems, Inc. | Probiotic/prebiotic composition and delivery method |
| PL1638416T3 (pl) * | 2003-06-23 | 2013-09-30 | Nestec Sa | Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej |
| ES2314461T3 (es) * | 2003-10-24 | 2009-03-16 | N.V. Nutricia | Composicion simbiotica para bebes. |
| WO2005055944A2 (en) | 2003-12-05 | 2005-06-23 | Cincinnati Children's Hospital Medical Center | Oligosaccharide compositions and use thereof in the treatment of infection |
| US7137361B2 (en) | 2004-06-22 | 2006-11-21 | Federal-Mogul World Wide, Inc. | Cylinder head gasket with one-way coolant flow valve |
| EP1714660A1 (en) | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
| EP1776877A1 (en) * | 2005-10-21 | 2007-04-25 | N.V. Nutricia | Method for stimulating the intestinal flora |
| PL1993577T3 (pl) * | 2006-03-10 | 2014-07-31 | Nutricia Nv | Stosowanie nieulegających trawieniu sacharydów dla zapewnienia niemowlęciu najlepszego startu po narodzinach |
| CN101668437A (zh) | 2007-03-13 | 2010-03-10 | N.V.努特里奇亚 | 使用含有非消化性糖的组合物改善能力的方法 |
| US8197872B2 (en) * | 2007-05-17 | 2012-06-12 | The Regents Of The University Of California | Human milk oligosaccharides to promote growth of beneficial gut bacteria |
| EP2072052A1 (en) | 2007-12-17 | 2009-06-24 | Nestec S.A. | Prevention of opportunistic infections in immune-compromised subjects |
| EP2072053B1 (en) * | 2007-12-21 | 2012-11-07 | Compagnie Gervais Danone | Method for decreasing abdominal girth by administering a bifidobacterium bacteria |
-
2007
- 2007-12-17 EP EP07123390A patent/EP2072052A1/en not_active Withdrawn
-
2008
- 2008-06-16 PH PH12010501367A patent/PH12010501367B1/en unknown
- 2008-12-05 MY MYPI2010002780A patent/MY185938A/en unknown
- 2008-12-05 CA CA2709396A patent/CA2709396A1/en not_active Abandoned
- 2008-12-05 US US12/808,053 patent/US9217133B2/en active Active
- 2008-12-05 SG SG2012092268A patent/SG186657A1/en unknown
- 2008-12-05 PL PL08862982.9T patent/PL2234627T3/pl unknown
- 2008-12-05 WO PCT/EP2008/066850 patent/WO2009077352A1/en active Application Filing
- 2008-12-05 RU RU2010129685/15A patent/RU2486910C2/ru active
- 2008-12-05 BR BRPI0820837-9A patent/BRPI0820837A2/pt not_active Application Discontinuation
- 2008-12-05 ES ES08862982.9T patent/ES2576642T3/es active Active
- 2008-12-05 CN CN2008801249067A patent/CN101909644A/zh active Pending
- 2008-12-05 MX MX2010006690A patent/MX2010006690A/es active IP Right Grant
- 2008-12-05 AU AU2008337646A patent/AU2008337646B2/en active Active
- 2008-12-05 EP EP08862982.9A patent/EP2234627B1/en not_active Revoked
- 2008-12-05 PT PT88629829T patent/PT2234627T/pt unknown
- 2008-12-08 UA UAA201008634A patent/UA102830C2/ru unknown
-
2010
- 2010-06-16 IN IN4311DEN2010 patent/IN2010DE04311A/en unknown
- 2010-07-16 ZA ZA2010/05088A patent/ZA201005088B/en unknown
-
2012
- 2012-08-17 US US13/588,745 patent/US20120308527A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010006690A (es) | 2010-09-10 |
| US20120308527A1 (en) | 2012-12-06 |
| UA102830C2 (ru) | 2013-08-27 |
| US9217133B2 (en) | 2015-12-22 |
| EP2072052A1 (en) | 2009-06-24 |
| PH12010501367B1 (en) | 2009-06-25 |
| RU2486910C2 (ru) | 2013-07-10 |
| CA2709396A1 (en) | 2009-06-25 |
| PL2234627T3 (pl) | 2016-12-30 |
| SG186657A1 (en) | 2013-01-30 |
| MX315565B (ru) | 2010-09-10 |
| IN2010DE04311A (ru) | 2010-11-12 |
| EP2234627B1 (en) | 2016-05-25 |
| CN101909644A (zh) | 2010-12-08 |
| ES2576642T3 (es) | 2016-07-08 |
| EP2234627A1 (en) | 2010-10-06 |
| ZA201005088B (en) | 2017-03-27 |
| US20100260720A1 (en) | 2010-10-14 |
| MY185938A (en) | 2021-06-14 |
| AU2008337646A1 (en) | 2009-06-25 |
| WO2009077352A1 (en) | 2009-06-25 |
| AU2008337646B2 (en) | 2014-07-17 |
| PT2234627T (pt) | 2016-07-26 |
| BRPI0820837A2 (pt) | 2015-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010129685A (ru) | Предупреждение оппортунистических инфекций у индивидуумов с нарушенным иммунитетом | |
| RU2010142003A (ru) | Синбиотическая смесь | |
| ES2652464T3 (es) | Composiciones que comprenden componentes probióticos y prebióticos y sales minerales, con lactoferrina | |
| RU2008136876A (ru) | Применение bifidobacterium longum для предупреждения и лечения воспаления | |
| RU2010153257A (ru) | Пробиотики для улудшения микробиоты пищеварительного тракта | |
| US11478515B2 (en) | Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin | |
| Yen et al. | Lactoferrin: an iron-binding antimicrobial protein against Escherichia coli infection | |
| RU2013128570A (ru) | Олигосахаридная композиция для лечения острых инфекций дыхательных путей | |
| Brüssow | Growth promotion and gut microbiota: insights from antibiotic use | |
| RU2012111253A (ru) | Bifidobacterium longum и функциональные расстройства желудочно-кишечного тракта | |
| AU2016312870B2 (en) | Composition and method for treatment and prophylaxis of intestinal infection and inflammation | |
| RU2017133795A (ru) | Композиции для применения в профилактике или лечении инфекций/воспалений в желудочно-кишечном тракте у младенцев или детей младшего возраста | |
| Hatakka et al. | Probiotics in intestinal and non-intestinal infectious diseases-clinical evidence | |
| RU2011106319A (ru) | Пробиотики для увелечения секреции iga у младенцев, рожденных посредством кесарева сечения | |
| RU2009139657A (ru) | Снижение риска диареи | |
| RU2008139598A (ru) | Синбиотическая смесь | |
| RU2010123174A (ru) | Профилактика и лечение вторичных инфекций после вирусной инфекции | |
| RU2017134672A (ru) | Композиции для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста | |
| JP2012520325A5 (ru) | ||
| JP2014512376A (ja) | 胃酸過多症の薬理学的処置中に失われる胃のバリア効果を回復させることができるプロバイオティック細菌を含む組成物 | |
| RU2009139669A (ru) | Синбиотик для улучшения кишечной микробиоты | |
| RU2010123176A (ru) | Применение олигосахаридов, содержащих n-ацетиллактозамин, для развития иммунных ответов у новорожденных | |
| RU2009100890A (ru) | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий | |
| IT201900014388A1 (it) | Consorzio di probiotici | |
| RU2011150189A (ru) | Профилактика и лечение аллергической диареи |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| QZ41 | Official registration of changes to a registered agreement (patent) |
Free format text: LICENCE FORMERLY AGREED ON 20101006 Effective date: 20150710 |
|
| QC41 | Official registration of the termination of the licence agreement or other agreements on the disposal of an exclusive right |
Free format text: LICENCE FORMERLY AGREED ON 20101006 Effective date: 20170316 |
|
| PC43 | Official registration of the transfer of the exclusive right without contract for inventions |
Effective date: 20190916 |